Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.47 |
| ▸ | TYMS | P04818 | 5/20 | 0.45 |
| ▸ | DHFR | P00374 | 11/20 | 0.42 |
| ▸ | FPGS | Q05932 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8873096 | 0.85 | QTRT1 (0.49) | QTRT1TYMSDHFR | |
| SCHEMBL8874179 | 0.75 | DHFR (0.45) | TYMSDHFRFPGS | |
| SCHEMBL6912192 | 0.74 | TYMS (0.50) | QTRT1TYMSDHFR | |
| SCHEMBL8872977 | 0.72 | QTRT1 (0.49) | QTRT1TYMSDHFRFPGS | |
| SCHEMBL28932180 | 0.71 | TYMS (0.56) | QTRT1TYMSDHFR | |
| SCHEMBL9954708 | 0.70 | TYMS (0.50) | QTRT1TYMSDHFRFPGS | |
| SCHEMBL30518413 | 0.70 | DHFR (0.70) | TYMSDHFR | |
| SCHEMBL103994 | 0.67 | QTRT1 (1.00) | QTRT1TYMS | |
| SCHEMBL27812021 | 0.67 | TYMS (0.46) | QTRT1TYMSDHFRFPGS | |
| SCHEMBL28787846 | 0.67 | TYMS (0.54) | QTRT1TYMSDHFRFPGS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594900-A2 | COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CANCERS | Salmedix, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040247600-A1 | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers | CEPHALON, INC. | 2004-12-09 | — | — | US | claimed |
| WO-2004074325-A2 | COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CANCERS | SALMEDIX, INC (US) | 2004-09-02 | — | — | WO | claimed |
| US-20040127435-A1 | Uses for inhibitors of inosine monophosphate dehydrogenase | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-07-01 | — | — | US | claimed |
| US-20040096436-A1 | Method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a member selected from an inhibitor of a protein kinase, an enantiomer of such a compound, a prodrug of such a | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-05-20 | — | — | US | claimed |
| WO-2004012746-A2 | NEW USES FOR INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-02-12 | — | — | WO | claimed |
| WO-2004012769-A1 | THERAPEUTIC INHIBITIONOF PROTEIN KINASES IN CANCER CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-02-12 | — | — | WO | claimed |
| US-7157551-B2 | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers | CEPHALON, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1594900-A2 | COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CANCERS | Salmedix, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040247600-A1 | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers | CEPHALON, INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004074325-A2 | COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CANCERS | SALMEDIX, INC (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040127435-A1 | Uses for inhibitors of inosine monophosphate dehydrogenase | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-07-01 | — | — | US | disclosed |
| US-20040096436-A1 | Method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a member selected from an inhibitor of a protein kinase, an enantiomer of such a compound, a prodrug of such a | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-05-20 | — | — | US | disclosed |
| WO-2004012746-A2 | NEW USES FOR INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004012769-A1 | THERAPEUTIC INHIBITIONOF PROTEIN KINASES IN CANCER CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040096436-A1 | Method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a member selected from an inhibitor of a protein kinase, an enantiomer of such a compound, a prodrug of such a | IMPDH1, IMPDH2, DCK | QTRT1 1554/4885TYMS 70/4885DHFR 113/4885 |
| US-20040127435-A1 | Uses for inhibitors of inosine monophosphate dehydrogenase | IMPDH1, IMPDH2, IMPA1 | QTRT1 707/4885TYMS 54/4885DHFR 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.